124
Participants
Start Date
January 27, 2022
Primary Completion Date
March 28, 2023
Study Completion Date
April 14, 2023
Insulin glargine/Lixisenatide
Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
University of Tennessee Health Science Center-Site Number:8400017, Memphis
University of Texas Southwestern Medical Center-Site Number:8400018, Dallas
Northeast Clinical Research of San Antonio LLC-Site Number:8400019, Schertz
University Clinical Investigators Inc-Site Number:8400020, Tustin
Clearview Medical Research LLC-Site Number:8400003, Canyon Country
National Research Institute - ClinEdge - PPDS-Site Number:8400004, Huntington Park
National Research Institute - ClinEdge - PPDS-Site Number:8400009, Huntington Park
Torrance Clinical Research Institute-Site Number:8400008, Lomita
Downtown LA Research Center Inc - ClinEdge - PPDS-Site Number:8400001, Los Angeles
San Fernando Valley Health Institute - ClinEdge - PPDS-Site Number:8400012, West Hills
Premier Research Associate-Miami-Site Number:8400002, Miami
Floridian Research Institute-Site Number:8400013, Miami
Palm Research Center, Inc.-Site Number:8400005, Las Vegas
Hassman Research Institute - HRI - Berlin - CenExel - PPDS-Site Number:8400007, Berlin
Mid Hudson Medical Research PLLC-Site Number:8400014, New Windsor
Endocrinology Associates Inc-Site Number:8400011, Columbus
Flourish Research - San Antonio - PPDS-Site Number:8400006, San Antonio
Consano Clinical Research LLC-Site Number:8400010, Shavano Park
Lead Sponsor
Sanofi
INDUSTRY